A number of other analysts have also recently commented on the stock. HC Wainwright set a $7.00 target price on shares of Mesoblast and gave the stock a buy rating in a research note on Friday, August 30th. Zacks Investment Research cut shares of Mesoblast from a buy rating to a hold rating in a research note on Friday, September 6th. Oppenheimer set a $10.00 price objective on shares of Mesoblast and gave the company a buy rating in a research note on Tuesday, September 10th. Maxim Group reaffirmed a buy rating and set a $16.00 price objective on shares of Mesoblast in a research note on Thursday, September 12th. Finally, Chardan Capital set a $6.00 price objective on shares of Mesoblast and gave the company a hold rating in a research note on Friday, August 30th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Mesoblast presently has a consensus rating of Buy and an average price target of $11.67.
MESO stock opened at $6.86 on Monday. The stock has a market capitalization of $698.75 million, a P/E ratio of -7.53 and a beta of 1.77. The firm has a 50-day simple moving average of $5.33 and a 200-day simple moving average of $5.18. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.14. Mesoblast has a 52 week low of $3.35 and a 52 week high of $8.78.
A hedge fund recently raised its stake in Mesoblast stock. Morgan Stanley boosted its holdings in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,702 shares of the company’s stock after acquiring an additional 109,295 shares during the period. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Read More: Capital gains and your 401(k) or IRA
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.